The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will compress -17.7% and EPS will contract -20.2%.
The average estimate for revenue is $6.94 billion. On the bottom line, the average EPS estimate is $1.38.
Last quarter, AstraZeneca recorded revenue of $7.35 billion. GAAP reported sales were 11% lower than the prior-year quarter's $8.29 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.81. GAAP EPS of $1.28 for Q1 were 38% lower than the prior-year quarter's $2.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 82.0%, 200 basis points worse than the prior-year quarter. Operating margin was 39.6%, 310 basis points worse than the prior-year quarter. Net margin was 22.3%, 1,280 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $28.80 billion. The average EPS estimate is $5.90.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 44 members out of 49 rating the stock outperform, and five members rating it underperform. Among three CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give AstraZeneca a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $48.39.
Can your retirement portfolio provide you with enough income to last? You'll need more than AstraZeneca. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.